From Isotope to Impact: 211At
Update: 2025-08-22
Description
Is it really happening? Astatine-211 is a promising new radionuclide being further developed and researched for the treatment of cancer. It is a short half-life alpha-emitter that's attracting more interest from the nuclear medicine community as investors take notice of its potential and production capacity improves. So where will 211At be by 2030? And is this a radionuclide that could show up in a clinical setting in the near future? Join host Ken Herrmann, MD with guests Brenda Sandmaier, MD, Tadashi Watabe, MD, and Ferid Haddad PhD, as they discuss the future of this isotope.
This episode is sponsored by IBA Radiopharma Solutions (https://www.iba-radiopharmasolutions.com/) and Accelerate.eu (https://ihi-accelerate.eu/)
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
